Source-grounded facts extracted from Core Laboratories Inc. /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kwaku Temeng resigned as director at Core Laboratories Inc. /DE/.
“On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the “Company”) of his intention to resign as a director of the Company effective October 1, 2026.”
Core Laboratories Inc. /DE/ shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-12 meeting.
“Proposal 3 – Approving the Compensation of the Company’s Named Executive Officers : An advisory vote on the compensation of the Company’s named executive officers was approved as follows: For Against Abstentions Broker Non-Votes 38,265,683 1,263,224 107,495 2,077,874”
Core Laboratories Inc. /DE/ shareholders approved Ratification of appointment of KPMG as independent registered public accountant at the 2026-05-12 meeting.
“Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant : The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2026 was approved as follows: For Against Abstentions Broker Non-Votes 41,220,974 484,159 9,143 —”
Core Laboratories Inc. /DE/ shareholders approved Election of Class I Directors at the 2026-05-12 meeting.
“Proposal 1 – Election of Class I Directors : The election of each Class I director was approved as follows: Nominee For Withheld Broker Non-Votes Harvey Klingensmith 35,880,017 3,756,385 2,077,874 Curtis Anastasio 39,271,486 364,916 2,077,874”
Core Laboratories Inc. /DE/ reported the first quarter of 2026 results: revenue $121.8 MILLION, EPS $0.02.
“results for the first quarter of 2026. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2026 RESULTS: • REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR • OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR • GAAP LOSS PER SHARE OF”
Core Laboratories Inc. /DE/: Lowered voting threshold for shareholder actions from 66-2/3% supermajority to simple majority (effective 2026-02-27).
“the only change being to lower the voting threshold set forth in Section 2.11 for approval of certain shareholder actions, including the approval of merger and change in control transactions, from a 66-2/3% supermajority vote to a 50% plus one simple majority vote”
Core Laboratories Inc. /DE/ shareholders approved Amendment and restatement of the Company's 2020 Long-Term Incentive Plan to increase shares and extend term through May 8, 2034 at the 2024-05-08 meeting.
“Proposal 4 – Approving the Amendment of the Company’s Long-Term Incentive Plan : The amendment and restatement of the Company’s 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through May 8, 2034, was approved as follows: For Against Abstentions Broker Non-Votes 36,742,268 1,468,975 105,308 2,919,136”
Core Laboratories Inc. /DE/ shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-08 meeting.
“Proposal 3 – Approving the Compensation of the Company’s Executive Officers : An advisory vote on the compensation of the Company’s named executive officers was approved as follows: For Against Abstentions Broker Non-Votes 36,411,684 1,822,497 82,370 2,919,136”
Core Laboratories Inc. /DE/ shareholders approved Ratification of appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2024 at the 2024-05-08 meeting.
“Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant : The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2024 was approved as follows: For Against Abstentions Broker Non-Votes 40,402,356 802,763 30,568 —”
Core Laboratories Inc. /DE/ shareholders approved Election of Class III Directors: Lawrence Bruno and Kwaku Temeng at the 2024-05-08 meeting.
“Proposal 1 – Election of Class III Directors : The election of each Class III director was approved as follows: Nominee For Withheld Broker Non-Votes Lawrence Bruno 37,354,023 962,528 2,919,136 Kwaku Temeng 33,030,809 5,285,742 2,919,136”
Core Laboratories Inc. /DE/ reported first quarter of 2024 results: revenue $129,600,000, EPS $0.07.
“for the first quarter of 2024. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2024 RESULTS: • FIRST QUARTER REVENUE OF $129.6 MILLION, UP MODESTLY SEQUENTIALLY AND YEAR-OVER-YEAR • FIRST QUARTER OPERATING INCOME OF $8.6 MILLION; EX-ITEMS, $14.9 MILLION, FLAT SEQUENTIALLY, UP 3% YEAR-OVER-YEAR • FIRST QUARTER”
Sow Hang Teo was appointed as Vice President and Chief Accounting Officer at Core Laboratories Inc. /DE/.
“Effective March 21, 2024, the Board approved the appointment of Mr. Sow Hang Teo to serve as the Company’s Vice President and Chief Accounting Officer.”
Kevin Daniels resigned as Vice President and Chief Accounting Officer at Core Laboratories Inc. /DE/.
“On March 21, 2024, Mr. Kevin Daniels announced his intention to resign as Vice President and Chief Accounting Officer of Core Laboratories Inc. (the “Company”) to pursue other opportunities.”
Core Laboratories Inc. /DE/ reported for the quarter and year ended December 31, 2023 results: revenue $128,210, net income $2,434, EPS $0.05.
“OF OPERATIONS (In thousands, except per share data) (Unaudited) Quarter Ended % Variance December 31, 2023 September 30, 2023 December 31, 2022 vs. Q3-2023 vs. Q4-2022 REVENUE $ 128,210 $ 125,343 $ 127,571 2.3% 0.5% OPERATING EXPENSES: Costs of services and product sales 101,517 96,617 99,816 5.1% 1.7% General and administrative expense 8,665 9,452 8,724 (8.3)%”
Core Laboratories Inc. /DE/ reported year ending December 31, 2023 results: revenue $510.0 million, EPS $0.86.
“• FOURTH QUARTER FREE CASH FLOW OF $16.7 MILLION • FOURTH QUARTER DEBT REDUCED BY $15.0 MILLION OR OVER 8% • COMPANY ANNOUNCES Q1 2024 QUARTERLY DIVIDEND • FULL YEAR REVENUE OF $510.0 MILLION, UP 4% • FULL YEAR OPERATING INCOME OF $54.6 MILLION; EX-ITEMS, $61.2 MILLION, UP 36% • FULL YEAR GAAP EPS OF $0.86; EX-ITEMS, EPS OF $0.80, UP 40% HOUSTON (January 31, 2024) -”
Core Laboratories Inc. /DE/ reported fourth quarter of 2023 results: revenue $128,200,000, EPS $0.14.
“31, 2023. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2023 RESULTS: • FOURTH QUARTER REVENUE OF $128.2 MILLION, UP 2% SEQUENTIALLY • FOURTH QUARTER OPERATING INCOME OF $14.6 MILLION; EX-ITEMS, $15.0 MILLION, DOWN 6% SEQUENTIALLY • FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% •”
Core Laboratories Inc. /DE/ reported second quarter of 2023 results: revenue $127,900,000, EPS $0.48.
“results for the second quarter of 2023. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2023 RESULTS: • REVENUE OF $127.9 MILLION; FLAT SEQUENTIALLY; UP 6% YEAR-OVER-YEAR • OPERATING INCOME OF $18.9 MILLION; EX-ITEMS, $15.6 MILLION, UP 8% SEQUENTIALLY; UP OVER 60% YEAR-OVER-YEAR • OPERATING MARGINS OF 15%;”
Core Laboratories Inc. /DE/ terminated Equity Distribution Agreement with Wells Fargo Securities LLC and BofA Securities Inc. valued at $60,000,000 (effective 2023-07-17).
“On July 17, 2023, Core Laboratories Inc. (the “Company”), terminated the Equity Distribution Agreement dated June 9, 2022 (the “Distribution Agreement”).”
Core Laboratories Inc. /DE/ shareholders approved Amendment and restatement of 2014 Non-Employee Director Stock Incentive Plan to extend term through June 28, 2033 at the 2023-06-28 meeting.
“Proposal 4 – Approve Extension of the Director Plan : The amendment and restatement of the Director Plan, the principal purpose of which is to extend the term of the Director Plan through June 28, 2033 was approved as follows: For Against Abstentions Broker Non-Votes 36,300,313 1,801,924 139,301 3,280,551”
Core Laboratories Inc. /DE/ shareholders approved Advisory vote on frequency of shareholder votes on executive compensation at the 2023-06-28 meeting.
“Proposal 3b – Approving the Frequency of Compensation of the Company’s Executive Officers : The selection of the frequency of shareholder votes on the compensation of the Company’s named executive officers was determined as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 35,944,561 10,314 2,247,398 39,265 3,280,551”
Core Laboratories Inc. /DE/ shareholders approved Advisory vote to approve compensation of executive officers at the 2023-06-28 meeting.
“Proposal 3a – Approving the Compensation of the Company’s Executive Officers : The compensation of the Company’s named executive officers was approved, on an advisory basis, as follows: For Against Abstentions Broker Non-Votes 36,172,862 1,265,529 803,147 3,280,551”
Core Laboratories Inc. /DE/ shareholders approved Ratification of appointment of KPMG LLP as independent registered public accountants at the 2023-06-28 meeting.
“Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant: The ratification of the appointment of KPMG as the independent registered public accountant for the fiscal year ending December 31, 2023 was approved as follows: For Against Abstentions Broker Non-Votes 40,549,322 910,252 62,515 —”
Core Laboratories Inc. /DE/ shareholders approved Election of Class I Directors at the 2023-06-28 meeting.
“Proposal 1 – Election of Class I Directors : The election of each Class I director was approved as follows: Nominee For Withheld Broker Non-Votes Harvey Klingensmith 33,648,480 4,593,058 3,280,551 Curtis Anastasio 37,297,840 943,698 3,280,551”
Core Laboratories Inc. /DE/ incurred senior notes of $50 million in aggregate principal amount with purchasers of the Notes at 7.25% and 7.50% maturing 2028 and 2030.
“On May 4, 2023, Core Laboratories Inc. (the “Company”) and Core Laboratories (U.S.) Interests Holdings, Inc. (the “Issuer”) completed a private placement of $50 million in aggregate principal amount of the Issuer’s senior secured notes with $25 million due 2028 (the “2028 Notes”) at an interest rate of 7.25% and $25 million due 2030 (the “2030 Notes”) at an interest rate of 7.50%.”
Core Laboratories Inc. /DE/ entered into Note Purchase Agreement with the purchasers of the Notes valued at $50 million (effective 2023-05-04).
“The terms of the Notes are governed by a Note Purchase Agreement dated May 4, 2023 (the “Agreement”), between the Company, the Issuer and the purchasers of the Notes.”
Core Laboratories Inc. /DE/ incurred senior notes.
“Pursuant to the Transaction, as of May 1, 2023, Core Lab Delaware assumed Core Lab N.V.’s obligations under the Eighth Amended and Restated Credit Agreement, as amended, and outstanding notes, including the 2011 Senior Notes and the 2021 Senior Notes, and certain other obligations and liabilities of Core Lab N.V. have been transferred to Core Lab Delaware.”
Core Laboratories Inc. /DE/ incurred credit facility.
“Pursuant to the Transaction, as of May 1, 2023, Core Lab Delaware assumed Core Lab N.V.’s obligations under the Eighth Amended and Restated Credit Agreement, as amended, and outstanding notes, including the 2011 Senior Notes and the 2021 Senior Notes, and certain other obligations and liabilities of Core Lab N.V. have been transferred to Core Lab Delaware.”
Core Laboratories Inc. /DE/ amended Amendment No. 2 to Note Purchase Agreement and Assumption Agreement (2011 Senior Notes and 2021 Senior Notes) with Holders of the notes under the Master Note Purchase Agreement dated September 30, 2011 and Note Purchase Agreement dated October 16, 2020 valued at Core Lab Delaware assumed all rights, obligations and liabilities of Core Lab N.V. and reaffirmed te (effective 2023-05-01).
“Amendment to Note Purchase Agreements On May 1, 2023, in connection with the Transaction, Core Lab Delaware and Core Laboratories U.S., and each of the holders of the notes (collectively, the “Noteholders”) under (i) the Master Note Purchase Agreement dated as of September 30, 2011 (the “2011 Senior Notes”), and (ii) the Note Purchase Agreement dated as of October 16, 2020 (the “2021 Senior Notes”, and together with the 2011 Senior Notes, collectively, the “Notes”), entered into, respectively, (a) an Amendment No. 2 to Note Purchase Agreement and Assumption Agreement in respect of the 2011 Senior Notes and (b) an Amendment No. 2 to Note Purchase Agreement and Assumption Agreement in respect of the 2021 Senior Notes (collectively, the “Second Amendments”).”
Core Laboratories Inc. /DE/ amended Consent and Amendment No. 1 to Eighth Amended and Restated Credit Agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender, Letter of Credit Issuer and Collateral Agent, and the other lenders party to the Credit Facility valued at Amendment to Credit Facility consenting to Merger of Core Lab N.V. into Core Lab Luxembourg, replaci (effective 2023-04-28).
“Item 1.01 Entry into a Material Definitive Agreement. Amendment to Credit Agreement On April 28, 2023, Core Lab N.V. and Core Laboratories (U.S.) Interests Holdings, Inc. (“Core Laboratories U.S.”) as borrowers, Bank of America, N.A., as Administrative Agent, Swing Line Lender, Letter of Credit Issuer and Collateral Agent, and the other lenders party to the Eighth Amended and Restated Credit Agreement dated as of July 25, 2022 (as amended, the “Credit Facility”) entered into a Consent and Amendment No. 1 (the “Amendment”) to the Credit Facility, pursuant to which the Administrative Agent and each of the lenders party to the Credit Facility (collectively, the “Lenders”) consented to the Merger of Core Lab N.V. into Core Lab Luxembourg, as contemplated by the Transaction, and agreed to make conforming amendments to the Credit Facility to, among other things, replace Core Lab N.V. with Core Lab Delaware as the successor parent borrower thereunder.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.